University College London
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered promising results in treating patients with an aggressive blood cancer, in results from a clinical trial led by researchers at UCL and UCLH.
Results from the FELIX trial, sponsored by Autolus Therapeutics and published in the New England Journal of Medicine, show how a second-generation CAR-T cell therapy, known as obecabtagene autoleucel (obe-cel), has reduced immune toxicity and persists for longer in patients - overcoming two common limitations of earlier CAR-T cell therapies.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
